Press Release 01.2020
Oncoinvent AS today announced it has completed a 40 million NOK round of financing. Hadean Ventures led the investment round with participation from existing investors CGS Holding AS, Helene Sundt AS, Alpine Capital AS, Artal AS, and Sciencons AS. The investment brings Oncoinvent’s total funding to 268 million NOK and will help the company aggressively pursue clinical development of its lead product candidate Radspherin®. Dr. Ingrid Teigland Akay, Managing Partner of Hadean Ventures will join the Oncoinvent Board of Directors.